Education
About Us
Working with TipRanks
Follow Us
Atara Biotherapeutics Inc (ATRA)
:ATRA
ATRA Analyst Ratings
Moderate Buy
2 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ATRA Stock 12 Month Forecast
Average Price Target
$17.50
▲(10.83% Upside)
| Highest Price Target$18.00 | Average Price Target$17.50 | Lowest Price Target$17.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Mizuho Securities
$16→$18
Buy
14.00%
Upside
Reiterated
11/20/25
Canaccord Genuity
$17
Buy
7.66%
Upside
Reiterated
11/13/25
Potential FDA Approval of Atara's Tab-cel Therapy: A Game-Changer for Future Growth and CAR T Program RevitalizationWe remain optimistic about the likelihood of FDA approval for tab-cel, as EBV+ PTLD is an ultra-rare indication and we believe Atara has been able to address manufacturing concerns raised by the FDA. Importantly, Atara has been able to show comparability with additional clinical data, but a request for even more clinical data (or a new Phase 3 trial) from the FDA remains a risk, although moderate in our view.
H.C. Wainwright
―
Hold
―
Reiterated
08/19/25
Wells Fargo
$3
Hold
-81.00%
Downside
Reiterated
03/11/25
TD Cowen
―
Buy
―
Reiterated
03/09/25
Rodman & Renshaw
$25→$7
Hold
-55.67%
Downside
Downgraded
01/21/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Mizuho Securities
$16→$18
Buy
14.00%
Upside
Reiterated
11/20/25
Canaccord Genuity
$17
Buy
7.66%
Upside
Reiterated
11/13/25
Potential FDA Approval of Atara's Tab-cel Therapy: A Game-Changer for Future Growth and CAR T Program RevitalizationWe remain optimistic about the likelihood of FDA approval for tab-cel, as EBV+ PTLD is an ultra-rare indication and we believe Atara has been able to address manufacturing concerns raised by the FDA. Importantly, Atara has been able to show comparability with additional clinical data, but a request for even more clinical data (or a new Phase 3 trial) from the FDA remains a risk, although moderate in our view.
H.C. Wainwright
―
Hold
―
Reiterated
08/19/25
Wells Fargo
$3
Hold
-81.00%
Downside
Reiterated
03/11/25
TD Cowen
―
Buy
―
Reiterated
03/09/25
Rodman & Renshaw
$25→$7
Hold
-55.67%
Downside
Downgraded
01/21/25
Best Analysts Covering Atara Biotherapeutics
1 Month
xxx
Success Rate
15/38 ratings generated profit
Average Return
-4.01%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 39.47% of your transactions generating a profit, with an average return of -4.01% per trade.
3 Months
xxx
Success Rate
16/38 ratings generated profit
Average Return
-4.63%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 42.11% of your transactions generating a profit, with an average return of -4.63% per trade.
1 Year
Success Rate
15/38 ratings generated profit
Average Return
-6.82%
reiterated a buy rating last month
Copying John Newman's trades and holding each position for 1 Year would result in 39.47% of your transactions generating a profit, with an average return of -6.82% per trade.
2 Years
xxx
Success Rate
10/38 ratings generated profit
Average Return
-24.30%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 26.32% of your transactions generating a profit, with an average return of -24.30% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ATRA Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
1
1
0
0
0
Buy
2
2
1
2
2
Hold
9
8
4
7
10
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
12
11
5
9
12
Each month's total comprises the sum of three months' worth of ratings.
ATRA Financial Forecast
ATRA Stock Forecast FAQ
What is ATRA’s average 12-month price target, according to analysts?
Based on analyst ratings, Atara Biotherapeutics Inc’s 12-month average price target is 17.50.
What is ATRA’s upside potential, based on the analysts’ average price target?
Atara Biotherapeutics Inc has 10.83% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ATRA a Buy, Sell or Hold?
Atara Biotherapeutics Inc has a consensus rating of Moderate Buy which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
What is Atara Biotherapeutics Inc’s price target?
The average price target for Atara Biotherapeutics Inc is 17.50. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $18.00 ,the lowest forecast is $17.00. The average price target represents 10.83% Increase from the current price of $15.79.
The highest analyst price target is $18.00 ,the lowest forecast is $17.00. The average price target represents 10.83% Increase from the current price of $15.79.
What do analysts say about Atara Biotherapeutics Inc?
Atara Biotherapeutics Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
How can I buy shares of ATRA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.